Anebulo Pharmaceuticals Company Insiders
| ANEB Stock | USD 2.08 0.04 1.89% |
Anebulo Pharmaceuticals' insiders are aggressively buying. The analysis of the overall insider sentiment regarding Anebulo Pharmaceuticals suggests that all insiders are extremely bullish. Anebulo Pharmaceuticals employs about 2 people. The company is managed by 5 executives with a total tenure of roughly 5 years, averaging almost 1.0 years of service per executive, having 0.4 employees per reported executive.
Anebulo Pharmaceuticals' Insider Buying Vs Selling
100
Selling | Buying |
Latest Trades
| 2021-12-17 | Aron R English | Acquired 400 @ 6.59 | View | ||
| 2021-12-14 | Aron R English | Acquired 412 @ 5.89 | View | ||
| 2021-12-02 | Aron R English | Acquired 13836 @ 5.3 | View |
Monitoring Anebulo Pharmaceuticals' insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
Anebulo |
Anebulo Pharmaceuticals Management Team Effectiveness
The company has return on total asset (ROA) of (0.579) % which means that it has lost $0.579 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.0428) %, meaning that it created substantial loss on money invested by shareholders. Anebulo Pharmaceuticals' management efficiency ratios could be used to measure how well Anebulo Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. As of May 30, 2024, Return On Tangible Assets is expected to decline to -1.21. The current year's Return On Capital Employed is expected to grow to -1.16. At present, Anebulo Pharmaceuticals' Total Assets are projected to increase significantly based on the last few years of reporting. The current year's Net Tangible Assets is expected to grow to about 12.9 M, whereas Non Current Assets Total are forecasted to decline to 0.00.The current year's Common Stock Shares Outstanding is expected to grow to about 26.1 M, whereas Net Loss is forecasted to decline to (11.1 M).
Anebulo Pharmaceuticals Workforce Comparison
Anebulo Pharmaceuticals is number one stock in number of employees category among related companies. The total workforce of Health Care industry is presently estimated at about 19,792. Anebulo Pharmaceuticals adds roughly 2.0 in number of employees claiming only tiny portion of equities under Health Care industry.
Anebulo Pharmaceuticals Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Anebulo Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Anebulo Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Anebulo Pharmaceuticals insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
22nw Fund, Lp over a week ago Acquisition by 22nw Fund, Lp of 1703577 shares of Anebulo Pharmaceuticals at 0.125 subject to Rule 16b-3 | ||
Kenneth Cundy over two months ago Acquisition by Kenneth Cundy of 72613 shares of Anebulo Pharmaceuticals subject to Rule 16b-3 | ||
Kenneth Cundy over three months ago Acquisition by Kenneth Cundy of 72613 shares of Anebulo Pharmaceuticals at 2.78 subject to Rule 16b-3 | ||
English Aron R over three months ago Acquisition by English Aron R of 300000 shares of Anebulo Pharmaceuticals subject to Rule 16b-3 | ||
Cunningham Richard Anthony over six months ago Acquisition by Cunningham Richard Anthony of 600000 shares of Anebulo Pharmaceuticals subject to Rule 16b-3 | ||
Shah Bimal R over six months ago Acquisition by Shah Bimal R of 26097 shares of Anebulo Pharmaceuticals subject to Rule 16b-3 |
Anebulo Pharmaceuticals Notable Stakeholders
An Anebulo Pharmaceuticals stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Anebulo Pharmaceuticals often face trade-offs trying to please all of them. Anebulo Pharmaceuticals' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Anebulo Pharmaceuticals' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Richard Cunningham | CEO Director | Profile | |
| Rex CFA | CFO Sec | Profile | |
| Daniel George | Acting Officer | Profile | |
| Scott Anderson | Head Affairs | Profile | |
| Kenneth Cundy | Chief Officer | Profile |
About Anebulo Pharmaceuticals Management Performance
The success or failure of an entity such as Anebulo Pharmaceuticals often depends on how effective the management is. Anebulo Pharmaceuticals management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Anebulo management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Anebulo management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (1.16) | (1.21) | |
| Return On Capital Employed | (1.22) | (1.16) | |
| Return On Assets | (1.16) | (1.21) | |
| Return On Equity | (1.27) | (1.21) |
The data published in Anebulo Pharmaceuticals' official financial statements usually reflect Anebulo Pharmaceuticals' business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Anebulo Pharmaceuticals. For example, before you start analyzing numbers published by Anebulo accountants, it's critical to develop an understanding of what Anebulo Pharmaceuticals' liquidity, profitability, and earnings quality are in the context of the Biotechnology space in which it operates.
Please note, the presentation of Anebulo Pharmaceuticals' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Anebulo Pharmaceuticals' management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Anebulo Pharmaceuticals' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Anebulo Pharmaceuticals. Please utilize our Beneish M Score to check the likelihood of Anebulo Pharmaceuticals' management manipulating its earnings.
Anebulo Pharmaceuticals Workforce Analysis
Traditionally, organizations such as Anebulo Pharmaceuticals use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Anebulo Pharmaceuticals within its industry.Anebulo Pharmaceuticals Manpower Efficiency
Return on Anebulo Pharmaceuticals Manpower
| Revenue Per Employee | 0.0 | |
| Revenue Per Executive | 0.0 | |
| Net Loss Per Employee | 5.9M | |
| Net Loss Per Executive | 2.3M | |
| Working Capital Per Employee | 5.3M | |
| Working Capital Per Executive | 2.1M |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Anebulo Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in income. For information on how to trade Anebulo Stock refer to our How to Trade Anebulo Stock guide.Note that the Anebulo Pharmaceuticals information on this page should be used as a complementary analysis to other Anebulo Pharmaceuticals' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Stocks Directory module to find actively traded stocks across global markets.
Complementary Tools for Anebulo Stock analysis
When running Anebulo Pharmaceuticals' price analysis, check to measure Anebulo Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Anebulo Pharmaceuticals is operating at the current time. Most of Anebulo Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Anebulo Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Anebulo Pharmaceuticals' price. Additionally, you may evaluate how the addition of Anebulo Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Stocks Directory Find actively traded stocks across global markets | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation |
Is Anebulo Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Anebulo Pharmaceuticals. If investors know Anebulo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Anebulo Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.36) | Return On Assets (0.58) | Return On Equity (1.04) |
The market value of Anebulo Pharmaceuticals is measured differently than its book value, which is the value of Anebulo that is recorded on the company's balance sheet. Investors also form their own opinion of Anebulo Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Anebulo Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Anebulo Pharmaceuticals' market value can be influenced by many factors that don't directly affect Anebulo Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Anebulo Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Anebulo Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Anebulo Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.